Mevociclib

CAS No. 1816989-16-8

Mevociclib( SY-1365 )

Catalog No. M26471 CAS No. 1816989-16-8

Mevociclib is a highly selective covalent inhibitor of CDK7. SY-1365 possesses therapeutic potential in both hematological and solid tumors.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 262 In Stock
50MG 1485 In Stock
100MG 2520 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Mevociclib
  • Note
    Research use only, not for human use.
  • Brief Description
    Mevociclib is a highly selective covalent inhibitor of CDK7. SY-1365 possesses therapeutic potential in both hematological and solid tumors.
  • Description
    Mevociclib is a highly selective covalent inhibitor of CDK7. SY-1365 possesses therapeutic potential in both hematological and solid tumors.
  • In Vitro
    ——
  • In Vivo
    Animal Model:Mice, HCC70 xenograft model Dosage:20 mg/kg Administration:Intravenous injection, twice weekly, for 35 days Result:Inhibited tumor volume in vivo.
  • Synonyms
    SY-1365
  • Pathway
    Angiogenesis
  • Target
    CDK
  • Recptor
    Akt| caspase-3| JNK1| p44/42 MAPK| RhoGDI
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1816989-16-8
  • Formula Weight
    587.13
  • Molecular Formula
    C31H35ClN8O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 125 mg/mL (212.90 mM)
  • SMILES
    CN(C)C\C=C\C(=O)Nc1ccc(nc1)C(=O)N[C@@]1(C)CCC[C@H](C1)Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Kohno K, Ohashi E, et al. Anti-inflammatory effects of adenosine N1-oxide. J Inflamm (Lond). 2015 Jan 20;12(1):2.
molnova catalog
related products
  • Aminopurvalanol A

    Aminopurvalanol A is a competitive, selective and cell-permeable inhibitor of cyclin-dependent kinase (CDK) that potently inhibits Cyclin A/cdk2, Cyclin B/cdk1, Cyclin E/cdk2, and P35/cdk5 with IC50 of 33 nM, 33 nM, 28 nM and 20 nM, respectively.

  • CDK4/6-IN-6

    CDK4/6-IN-6 is a potent CDK4/CDK6 inhibitor with Ki of 0.6 nM and 13.9 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively.

  • ML365

    ML365 is a novel selective small molecule inhibitor of TASK1(KCNK3).